drugset
drugset / Trial / NCT01175707

Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting

NCT01175707 ↗

Phase 4 Terminated 80 enrolled Merck & Co., Inc.
RandomizedParallel-groupOpen-labelHealth-services research

Summary

This is a randomized, open-label, multi-center, phase 4 study designed to compare intravenous (IV) daptomycin and IV vancomycin administered in a home infusion setting for the treatment of complicated skin and skin structure infections (cSSSI) due to Gram-positive bacteria in participants who are prescribed vancomycin for 7 to 14 days and who are planning to receive vancomycin in a home-infusion setting.

Timeline

Start
2010-07-15
Primary completion
2011-11-17
Completion
2011-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 500 mg Intravenous
Comparator Vancomycin Other / unclassified — Intravenous

Indications

No indication recorded.